Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

FRANKFURT (Reuters) – Merck KGaA and Pfizer received a setback on Thursday for their drug Bavencio, which is a late starter in the rapidly evolving field of cancer immunotherapies.

Source: Reuters Medical News